Skip to main content

Table 3 Main methodological characteristics of randomized controlled trials included in the quantitative analysis (meta-analysis)

From: Medical treatment of cystic echinococcosis: systematic review and meta-analysis

Author/s. Year (Ref.no.) Location Country Objectivea Study design Trial time period Participants Sample size (N)b No. Cysts Patients characteristicsc
Bildik N, et al. 2007 [33] Kartal-Istanbul, Turkey To evaluate the efficacy of preoperative ABZ therapy A randomized controlled trial 1998–2003 Patients with isolated hydatid cysts of the liver 84 84 Sex (M/F), 36/48
Range age (yr), (14–67)
Group I Group II Group III Group IV-control group
n = 21
No.cyst = 21
n = 21
No.cyst = 21
n = 21
No.cyst = 21
n = 21
No.cyst = 21
Cobo F, et al. 1998 [9] Pamplona-Navarra, Spain To compare the effects of a combined medication of ABZ plus PZQ vs ABZ alone in the preoperative treatment A randomized controlled trial 1990–1997 Patients with intra-abdominal hydatidosis 62 → 47 No data   Group I Group II Group III
n
Sex (M/F)
Age (yr, mean ± SD[range])
Cyst/patient (mean[range])
19 → 12
6/6
47.9 (19–67)
1.17(1–3)
17 → 14
11/3
51.1 (31–70)
1.57 (1–4)
26 → 21
9/12
46.9 (18–75)
1.43 (1–5)
Davis A, et al. 1986 [34] WHO, Geneva, Switzerland First phase: Studies coordinated by the WHO were conducted in seven clinical centers on the chemotherapy of human echinococcosis with MBZ, ABZ and FBZ. A multicenter randomized clinical trials (5 clinical centers, Beirut, Paris, Rome, Sofia and Zurich) 1982–1984 Adults patients, mainly, only 7% below 15 years 121 121   MBZ FBZ ABZ
n = 121
Sex (M/F) = 63/58
No.cyst = 402
85
38/47
348
6
3/3
18
30
22/8
36
Davis A, et al. 1989 [35] WHO, Geneva, Switzerland Second phase: To value the efficacy of ABZ and MBZ in human CE coordinated by WHO. A multicenter randomized clinical trials (4 clinical centers, Beirut, Paris, Rome and Sofia) 1985–1987 Adults patients, mainly, only 4% below 15 years 176 → 112 106   ABZ MBZ
n = 112
Sex (M/F) = 47/65
Follow-up < 12 months = 44
Follow-up > 12 months = 68
No.cyst patients > 12 months = 106
67
27/40
21
46
76
45
20/25
23
22
30
Franchi C, et al. 1999 [36] Rome, Italy To evaluate the results obtained during long-term follow-up of a series of patients treated with benzimidazole carbamate A randomized controlled trial 1982–1997 Patients with hydatidosis located in various body organs 448 929 Sex (M/F), 191/257
Age (yr, mean[range]), 52 (4–86)
Follow-up (months, mean[range]), 22 (12–170)
  MBZ ABZ
n
No.cyst
125
289
323
640
Gil-Grande LA, et al. 1993 [37] Madrid, Spain To assess the efficacy and safety of ABZ in a medical treatment A randomized controlled trial 1987–1991 Patients with intra-abdominal hydatid disease 66 → 55 55   Group A Group B Control gr.
n
Sex (M/F)
Age (yr, mean ± SD)
No.cyst
18
10/8
41.7 ± 14.2
18
19
12/7
47.3 ± 13.9
19
18
9/9
41.2 ± 17.3
18
Keshmiri M, et al. 1999 [38] Mashhad, Iran To compare the effects of ABZ vs placebo in the treatment of hydatid cysts A triple-blind parallel randomized clinical trial 1994–1995 Patients with hydatid cysts of the lung/pulmonary echinococcosis 20All p.
15Treat.
179All p.
150Treat.
  Treatment group Placebo group
All p.d Treat.d All p.d Treat.d
n
Sex (M/F)
Age (yr, mean ± SD)
No.cyst
Cyst/patient
14
8/6
41 ± 15
137
12.2 ± 13.4
11
5/6
40 ± 17
124
16.3 ± 13.9
6
3/3
39 ± 17
42
10.8 ± 13.7
4
3/1
45 ± 17
26
8.8 ± 7.6
Keshmiri M, et al. 2001 [39] Mashhad, Iran To evaluate the effect of ABZ on hydatid disease A double-blind parallel-group randomized clinical trial 1994–1995 Patients with hydatid cysts of the lung and abdomen (including liver) 29All p.
21Treat.
240 All p.
203Treat.
  Treatment group Placebo group
All p.d Treat.d All p.d Treat.d
n
Sex (M/F)
Age (yr, mean ± SD)
No.cyst
Cyst/patient
22
11/11
41.4 ± 15.9
191
8.6 ± 9.0
17
7/10
40.5 ± 17.3
172
9.8 ± 9.9
7
4/3
35.4 ± 18.3
49
7.1 ± 6.5
4
3/1
45.5 ± 17.4
31
7.8 ± 6.1
Khuroo MS, et al. 1993 [40] Srinagar, Kashmir, India To compare the safety and efficacy of percutaneous drainage (PD) with ABZ therapy A randomized controlled trial 1989–1992 Patients with hepatic hydatid cysts 30 33   PD ABZ-PD ABZ
n
Sex (M/F)
Age (yr, mean ± SD)
(Range age)
No.cyst
Size Ø (cm, mean ± SD)
Volume (cm3, mean ± SD)
10
4/6
36.7 ± 12.3
(12–55)
10
9.2 ± 4.4
686 ± 651
10
3/7
41.3 ± 14.9
(12–64)
12
10.8 ± 3.0
835 ± 528
10
4/6
39.5 ± 14.4
(18–60)
11
8.8 ± 4.5
642 ± 717
Mohamed AE, et al. 1998 [8] Riyadh, Saudi Arabia To evaluate the effect of different regimens of medical treatment Two prospective randomized intervention studies 1st study, 1985–1990
2nd study, 1990–1998
Adult Saudi patients with hydatid disease at the Armed Forces Hospital 1st, 22
2nd, 19,
Total,41
No data 1st, ALB 2nd, ABZ+PZQ
n = 22 n = 19
Shams-UI-Bari, et al. 2011 [41] Srinagar, Kashmir, India To assess the effect of preoperative ABZ therapy on the viability of protoscoleces at the time of surgery A randomized controlled trial 2002–2003 + follow-up 5 years Patients with diagnosis of hydatid liver disease 72 72 Sex (M/F), 39/33
Range age (yr), (17–66)
  Group A-Surgery Group B-ABZ+surg+ABZ
n
Sex (M/F)
Age (yr, mean ± SD[range])
No.cyst
36
19/17
36.75 ± 11.34(16–64)
36
36
20/16
36.78 ± 11.79(17–62)
36
  1. aABZ Albendazole, PZQ Praziquantel, MBZ Mebendazol, FBZ Flubendazole
  2. bN start of the study→N the end of the study
  3. cM/F, Male/Female ratio
  4. dAll patients, Completed treatment